Drug intelligence / Profile preview

farletuzumab

Development stage: Phase 3
Lead developer: Eisai
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Farletuzumab is a humanized monoclonal antibody (IgG1) that targets the folate receptor alpha (FRα), which is overexpressed in various epithelial cancers, including ovarian cancer. It works through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Farletuzumab has been explored in clinical trials for epithelial ovarian cancer, often in combination with chemotherapy agents like carboplatin and paclitaxel.

Other names: Anti-GP-3 humanised mAbAnti-GP3 humanised mAbAnti-GP 3 humanised mAbAnti-GP3 humanised monoclonal antibodyAnti-GP-3 humanised monoclonal antibodyAnti-GP 3 humanised monoclonal antibody

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on farletuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on farletuzumab.

Explore the full profile